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Docking studyAbstract A new series of N-substituted azetidinones (9a–h) synthesized by condensation of 4-ary-
lidene hydrazino 1-isobutyl-1H-imidazo[4,5-c]quinolines (8a–h) with chloroacetyl chloride afforded
4-arylazetidin-2-ones (9a–h). The synthesized compounds were characterized by 1H NMR, 13C
NMR, mass spectral and elemental analyses. All synthesized compounds were screened for their
in vitro antimicrobial and anticancer activities. The hydrazone derivatives (8a–h) showed good anti-
bacterial activity. Compounds 9a and 9b exhibited good anticancer activity. In a molecular docking
study compounds 9a and 9b showed minimum binding energy and good afﬁnity towards the active
pocket. Thus, are believed to be good inhibitors of b-tubulin.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The recent literature is enriched with ﬁndings about pharmacolog-
ical activities of imidazoquinolines [1]. The synthesis of imidazo-
quinoline had been of increasing interest, since many of their
derivatives exhibited useful applications such as antimalarial [2],
anticonvulsant and antitumor agents [3]. Drugs with an imidazo-
quinoline motif include Imiquimod and Resiquimod (Fig. 1).
2-Azetidinones are an important class of heterocyclic com-
pounds with potent antibacterial activity. Modiﬁcation of the
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N
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N
N
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Figure 1 Structure of Imiquimod and Resiquimod.
Synthesis and characterization of imidazoquinoline based 2-azetidinones S435b-lactam ring leads to compounds with diverse pharmacologi-
cal activities, inducing cholesterol absorption inhibition,
human tryptase, thrombin and chymase inhibition, vasopres-
sin V1a antagonist activity, and antimicrobial, anticonvulsant
and anti-inﬂammatory activities [4–8]. The drugs with 2-aze-
tidinone scaffold are penicillins, cephalosporins, carbapenems,
nocardicins, monobactams, clavulanic acid, sulbactams and
tazobactams. These drugs had been used widely as chemother-
apeutic agents to treat various microbial diseases [9–16].
Most studies outlaying are focused on the synthesis and
pharmacological evaluations of imidazoquinoline and tetraim-
idazoquinoline compounds containing urea, thiourea, acylu-
rea, sulphonylurea, amide, sulphonamide, oxime or N-oxide
moieties at the 1-position [17–21].
Keeping in view of this and in continuation of our search
for biologically potent molecules [22] we have synthesized a
series of 3-chloro-4-arylsubstituted-1-[(1-isobutyl-1H-imi-
dazo[4,5-c]quinolin-4-yl)amino]azetidin-2-ones (9a–h) by
derivatization of imidazoquinoline at the 4-position and
assessed their antimicrobial and anticancer activities.
Some of the anticancer drugs showed activity by binding
selectively to b-tubulin, a protein subunit of microtubule and
thereby disrupting the microtubule structure and function.
Microtubules are highly dynamic, ubiquitous cellular organ-
elles serving a variety of vital functions including mitosis,
motility and transport in all eukaryotes. Many of these struc-
tures exist in a dynamic equilibrium in which assembly and dis-
assembly of the soluble subunits are balanced. In such systems,
the drug–btubulin interaction results in a net loss of microtu-
bules and accumulation of free tubulin. In view of the crucial
roles, that microtubules play in many cellular processes, their
drug-induced destruction eventually leads to the death of the
organism [23]. Molecular docking technique plays an impor-
tant role in discovering new drug molecules and predicting
the conformations of drug molecule at the active site, hence
in the present study, molecular docking studies of newly syn-
thesized compounds were carried out to predict the b-tubulin
inhibitory activity and results are reported.
2. Results and discussion
The synthesis of target compounds 9a–h is outlined in
(Scheme 1). Compound (4-chloro-1-isobutyl-1H-imidazo[4,5-c]
quinoline (6) was synthesized from 2,4 dihydroxyquinoline
(1) according to a previously reported procedure [24]. The
compound 4-hydrazino-1-isobutyl-1H-imidazo[4,5-c]quinoline
(7) was prepared by the reaction of hydrazine hydrate with
4-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline (6). The struc-
ture of 4-hydrazino-1-isobutyl-1H-imidazo[4,5-c]quinoline (7)
was conﬁrmed by IR, 1H NMR, 13C NMR, mass spectral data
and elemental analyses. The 1H NMR spectrum of 7 showed
singlet for NH at d 7.14 ppm and a broad peak for NH2 at d4.76 ppm. The IR spectrum of 7 showed absorption due to
NH2 at 3388, 3394 cm
1 and absence of the peak due to C–
Cl at 877.7 cm1 conﬁrming the structure of 7. The structure
of compound 7 was also conﬁrmed by a single crystal X-ray
study [25].
The treatment of 7 with various substituted aromatic alde-
hydes in ethanol afforded hydrazones namely; 4-(substituted
arylidenyliminoamino)1-isobutyl-1H-imidazo[4,5-c]quinolines
(8a–h). The IR, 1H NMR, 13C NMR, and mass spectral data
conﬁrmed the structures of 8a–h. The 1H NMR spectrum of
8a was characterized by the presence of CH‚N protons,
which appeared as a singlet at d 9.67 ppm. The IR spectrum
of 8a showed common characteristic absorption peaks at
3371 cm1 (NH) and 1590 cm1 (C‚N). The 13C spectrum
of 8a was characterized by the presence of CH‚N carbon at
d 152.40 ppm.
Compounds (8a–h) in DMF containing triethylamine were
reacted with chloroacetyl chloride to afford corresponding 3-
chloro-4-arylsubstituted-1-[(1-isobutyl-1H-imidazo[4,5-c]quin-
olin-4-yl)amino]azetidin-2-ones (9a–h). The 1H NMR spec-
trum of 9a was characterized by the absence of CH‚N
protons at d 9.67 ppm. The IR spectrum of 9a showed com-
mon characteristic absorption peaks at 1765 cm1 (C‚O)
and 762 (C–Cl). The absence of peaks due to (C‚N) con-
ﬁrmed the cyclization of 8a and formation of 9a. The reaction
of hydrazones with chloroacetyl chloride as per many earlier
literature reports was carried out in dioxane [26]. In contrast
to this, we have carried out the reaction in DMF [27]. A com-
parison of the effect of solvent and reaction time on yield of
9a–h was satisfactory Table 1. The reaction proceeded in a fas-
ter rate compared with the earlier reported procedure, yield
was satisfactory, and isolation was easier. Thus, makes the
modiﬁed synthetic procedure of great synthetic utility.
The spectral values for all the compounds and elemental
analyses are given in Section 5. The spectral studies and ele-
mental analyses of hydrazone and azetidinone derivatives were
in accordance with the proposed structure.
3. Biological screening
3.1. Antibacterial activity
The in vitro antibacterial activity of newly synthesized com-
pounds 7, 8a–h and 9a–h was determined by the cup plate
method (diffusion technique) [28]. In this work, Staphylococcus
aureus (Gram +ve), Escherichia coli (Gram ve), Streptococ-
cus faecalis, (Gram +ve) and Klebsiella pneumoniae (Gram
ve) were used to investigate the activity. The Procaine peni-
cillin was used against S. aureus, S. faecalis and the Streptomy-
cin was used against E. coli, K. pneumoniae as the standard
drugs. The standard drugs and synthesized compounds were
dissolved in a minimum quantity of DMF at concentrations
of 1 and 0.5 mg/ml.
The antibacterial screening of compounds 8a–h revealed
that substituents have a signiﬁcant role in the activity. Among
the synthesized compounds 7, 8a, 8b, 8c, 8f, 8g and 8h showed
excellent activity against gram positive and gram negative
strains. The activity of these compounds may be due to the
mono, di-substituted electron-donating and withdrawing
groups attached to a phenyl ring linked to azomethine. The
derivatives containing a tri-substituted group attached to the
Scheme 1 The sequential steps in the synthesis of azetidinones (9a–h).
S436 R. Kayarmar et al.phenyl ring linked to azomethine exhibited good activity
against gram negative strains, however, they were found to
possess poor activity against positive strains. These variations
in activity may be due to the presence of the electron-with-
drawing group along with the electron-donating group whichretards the activity. The antibacterial screening of com-
pounds 9a–h revealed that cyclization of hydrazones to aze-
tidinone ring showed excellent activity against gram
positive strains. The antibacterial results are summarized in
Table 2.
Table 1 Comparison of reaction time, yield data for synthesis
of (9a–h) in DMF/dioxane.
Entry Solvent Time (h) Yield (%)
9a DMFa/Dioxaneb 6c/24d 80e/20f
9b DMFa/Dioxaneb 6c/24d 90e/20f
9c DMFa/Dioxaneb 6c/24d 92e/20f
9d DMFa/Dioxaneb 6c/24d 92e/15
f
9e DMFa/Dioxaneb 6c/24d 50e/10f
9f DMFa/Dioxaneb 6c/24d 80e/12f
9g DMFa/Dioxaneb 6c/24d 60e/12f
9h DMFa/Dioxaneb 6c/24d 84e/18f
a,bReaction in DMF/dioxane.
cReaction temperature in DMF/ddioxane.
e,f Isolated yield by column puriﬁcation.
Synthesis and characterization of imidazoquinoline based 2-azetidinones S4373.2. Antifungal activity
The synthesized compounds were also tested for antifungal
activity by the diffusion method [29]. Candida albicans and
Aspergillus fumigatus were used as microorganisms. Ciclopir-
oxolamine was used as the standard drug. The standard drug
and synthesized compounds were dissolved in a minimum
quantity of dimethylformamide (DMF) at concentrations of
1 and 0.5 mg/ml.
The antifungal screening of compounds 7 and 8a–h showed
signiﬁcant inhibitory effects against A. fumigatus, but poor
inhibitory activity against C. albicans. The activity of com-
pounds 8a–h against fungi was not affected by different sub-
stituents and azomethine linkage. The antifungal results
revealed that position of e-withdrawing or donating group
on the phenyl ring of 2-azetidinone nucleus has no effect on
the activity of compounds 9a–h. Analogues 9b with the biphe-
nyl ring on the C-4 position of 2-azetidinone ring showedTable 2 Antibacterial activity of compounds 7, 8a–h and 9a–h.
Compounds Zone of inhibition in (mm)
S. aureus S. faecalis
0.5 mg/mL 1 mg/mL 0.5 mg/mL 1
7 17 (0.94) 19 (0.95) 17 (0.89) 19
8a 16 (0.88) 18 (0.99) 16 (0.88) 18
8b 17 (0.94) 19 (0.95) 17 (0.94) 19
8c 16 (0.88) 18 (0.90) 16 (0.88) 18
8d 11 (0.61) 13 (0.65) 11 (0.61) 13
8e 13 (0.72) 14 (0.70) 13 (0.72) 14
8f 15 (0.98) 17 (0.80) 15 (0.98) 17
8g 15 (0.83) 17 (0.80) 15 (0.83) 17
8h 17 (0.85) 15 (0.75) 17 (0.85) 15
9a 10 (0.55) 15 (0.75) 10 (0.55) 15
9b 11 (0.61) 12 (0.60) 11 (0.61) 12
9c 10 (0.55) 11 (0.55) 10 (0.55) 11
9d 10 (0.55) 12 (0.60) 10 (0.55) 12
9e 10 (0.55) 10 (0.50) 10 (0.55) 10
9f 11 (0.61) 13 (0.65) 11 (0.61) 13
9g 10 (0.55) 11 (0.55) 10 (0.55) 11
9h 10 (0.55) 13 (0.65) 10 (0.55) 13
Procaine penicillin 18 20 18 20
Streptomycin – – – –
DMF – – – –
The zone of inhibition in mm.potent activity on C. albicans and A. fumigatus. Compounds
9a, 9c, 9d, 9e, 9f, 9g and 9h containing electron withdrawing
or releasing substituents on the phenyl ring of 2-azetidinones
showed potent activity against A. fumigatus. The same ana-
logues exhibited moderate to poor activity against C. albicans.
The results are tabulated in Table 3.3.3. Anticancer activity
The anticancer activity of 7, 8a–h and 9a–h against the cancer
cell line, HeLa was measured by employing the Trypan blue
exclusion method. The anticancer activities of compounds
were measured with regard to control and compared with stan-
dard drug Cyclophosphamide (CP). All the pharmacological
data are expressed as IC50 (±SD). The experimental data
obtained were analysed for multiple comparisons using one-
way analysis of variance (ANOVA) followed by Dunnett’s
test. A signiﬁcant level of p< 0.05 was considered signiﬁcant
in all the cases. Results of IC50 values are expressed as
mean ± standard error of mean (SEM) and statistical analysis
was carried out using the Graph Pad Prism version 3.0.3.3.1. Cell culture
A stock solution of each test compound was prepared in
DMSO at a concentration of 1000 lg/ml. Initially, a wide
range of concentrations of each test compound in a log incre-
ment (1–1000 lg/ml) were used in cytotoxicity tests. Based on
the results from the ﬁrst range, concentrations in a narrower
range, i.e., 10–100 lg/ml (linear order) of the test compounds
were used in the subsequent tests. The selected concentrations
of each test compound were dissolved in DMSO. The conven-
tional anticancer drug, CP (0.5–10.0 lg/ml) was used as the
positive control.E. coli K. pneumoniae
mg/mL 0.5 mg/mL 1 mg/mL 0.5 mg/mL 1 mg/mL
(0.90) 17 (0.94) 19 (0.95) 17 (0.89) 19 (0.90)
(0.99) 18 (0.94) 20 (0.95) 18 (0.94) 20 (0.95)
(0.95) 16 (0.84) 18 (0.85) 16 (0.84) 18 (0.85)
(0.90) 18 (0.94) 19 (0.90) 18 (0.94) 19 (0.90)
(0.65) 17 (0.89) 18 (0.85) 17 (0.89) 18 (0.85)
(0.70) 15 (0.78) 17 (0.80) 15 (0.78) 17 (0.80)
(0.80) 18 (0.94) 20 (0.95) 18 (0.94) 20 (0.95)
(0.80) 17 (0.89) 19 (0.90) 17 (0.89) 19 (0.90)
(0.75) 15 (0.78) 20 (0.95) 15 (0.78) 20 (0.95)
(0.75) 18 (0.94) 19 (0.90) 18 (0.94) 19 (0.90)
(0.60) 18 (0.85) 17 (0.89) 18 (0.85) 17 (0.89)
(0.55) 17 (0.73) 20 (0.95) 17 (0.73) 20 (0.95)
(0.60) 18 (0.73) 17 (0.71) 18 (0.73) 17 (0.71)
(0.50) 17 (0.89) 20 (0.95) 17 (0.89) 20 (0.95)
(0.65) 18 (0.94) 19 (0.90) 18 (0.94) 19 (0.90)
(0.55) 17 (0.89) 20 (0.95) 17 (0.73) 20 (0.95)
(0.65) 18 (0.94) 20 (0.95) 18 (0.94) 20 (0.95)
– – –
19 21 19 21
– – – –
igure 2 Cytotoxic activity (IC-50 values) of test compounds 7,
a–h) and (9a–h) against HeLa cancer cells.
Table 3 Antifungal activity of compounds 7, 8a–h and 9a–h.
Compounds Zone of inhibition in (mm)
C. albicans A. fumigatus
0.5 mg/ml 1 mg/ml 0.5 mg/ml 1 mg/ml
7 13 (0.61) 17 (0.73) 17 (0.84) 20 (0.95)
8a 16 (0.76) 18 (0.78) 18 (0.94) 19 (0.90)
8b 14 (0.66) 17 (0.73) 16 (0.84) 18 (0.85)
8c 13 (0.61) 13 (0.61) 18 (0.94) 18 (0.85)
8d 12 (0.57) 16 (0.69) 16 (0.84) 17 (0.80)
8e 12 (0.57) 15 (0.65) 17 (0.89) 19 (0.90)
8f 16 (0.76) 17 (0.73) 18 (0.94) 19 (0.90)
8g 13 (0.61) 15 (0.65) 16 (0.84) 16 (0.84)
8h 12 (0.57) 15 (0.65) 18 (0.94) 18 (0.94)
9a 11 (0.52) 14 (0.65) 17 (0.89) 18 (0.85)
9b 19 (0.90) 21 (0.91) 16 (0.84) 18 (0.85)
9c 15 (0.71) 16 (0.69) 17 (0.89) 19 (0.90)
9d 12 (0.57) 14 (0.60) 16 (0.84) 18 (0.85)
9e 14 (0.66) 16 (0.69) 16 (0.84) 19 (0.90)
9f 13 (0.61) 15 (0.65) 17 (0.89) 19 (0.90)
9g 12 (0.57) 14 (0.60) 16 (0.84) 18 (0.85)
9h 13 (0.61) 16 (0.69) 18 (0.94) 19 (0.90)
Ciclopiroxolamine 21 23 19 21
DMF 0 0 0 0
The zone of inhibition in mm.
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HeLa cells in the exponential growth phase were washed with
phosphate buffered saline solution, trypsinized and resus-
pended in Dulbecco’s modiﬁed Eagle Medium. Cells were pla-
ted at a concentration of 30,000 cells/well in 6 well plates and
incubated for 24 h during which a partial monolayer formed.
The plates were incubated at 37 C in a humidiﬁed incubator
with 5% CO2 for a period of 24 h. After incubation, the cells
were exposed to the selected concentrations of the testTable 4 Anticancer activity data of analogues 7, 8a–h and
9a–h.
Anticancer activity – IC50
a values of 7, (8a–h) and (9a–h)
Compound. No IC50 values (lM)
7 18.17 ± 2.23
8a 24.3 ± 2.72
8b 13.6 ± 1.90
8c 21.33 ± 1.91
8d 27.5 ± 2.34
8e 19.27 ± 1.75
8f 30.47 ± 2.86
8g 24.23 ± 1.96
8h 26.41 ± 2.23
9a 11.47 ± 1.25
9b 11.77 ± 0.98
9c 24.67 ± 1.57
9d 22.0 ± 2.62
9e 34.13 ± 2.33
9f 21.4 ± 1.95
9g 16.53 ± 1.41
9h 17.76 ± 1.15
CPb 4.2 ± 0.431
a 50% inhibitory concentration.
b Cyclophosphamide as antiviral agent used as positive control.F
(8Figure 3 Structure of b-tubulin (PDB ID: 1OJ0).
Figure 4 Interaction of 9a with b-Tubulin.
Figure 5 Interaction of 9b with b-Tubulin.
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end of 24 h, 50 lL of the cell suspension was mixed with
50 lL of 0.4% trypan blue dye and left for 1–2 min at room
temperature. The non-viable (stained) and viable (unstained)
cells were counted using a hemo cytometer and the percentage
of dead cells were determined [30].
All the newly synthesized compounds were evaluated for
their anticancer activities using HeLa cell line. Among the
compounds, 9a and 9b were found to have a high anticancer
activity against HeLa cells. The test compounds, 7, 8b, 8e, 9g
and 9h exhibited moderate anticancer activity (>20 lg/ml).
The combination of an Imidazoquinoline moiety with biphenyl
linked through azomethine 8b (IC50 = 13.6) enhanced antitu-
mor activity when compare with other derivatives. The
cyclized analogues 9a, 9b, 9g, and 9h show an increased activ-
ity compared to uncyclized derivatives 8a, 8b, 8g, and 8h.
Compounds 9a and 9b inhibit HeLa cells at different concen-
trations, less than 15 lg/ml. In comparison, the IC50 values
obtained for the recommended drug candidates 9a and 9b from
the present study are approximately 3-fold less potent to
Cyclophosphamide. However, the efﬁcacy of any compound
cannot be compared directly with the conventional drug as it
depends on other factors, particularly the lethal toxicity [31].
Further studies on the determination of therapeutic index
based on comparison between the amount of the drug
candidates for the therapeutic effect and median lethal dose
in animals may give insight into the efﬁcacy of the compounds.
In addition, the mechanism of action is also an importantTable 6 ADMET properties of synthesized compounds 9a and 9b.
Molecules Mutagenic Tumorigenic Irritation Reprod
9a N N N N
9b N N N N
Cyclophosphamide H H H H
Table 5 Molecular docking results of compounds 9a and 9b with b
Molecules Binding
energy
Ligand
eﬃciency
Intermol
energy
Torsional
energy
RMS No
H b
9a 3.51 1.08 3.25 1.19 0.0 2
9b 1.16 0.15 1.93 1.49 0.0 1criterion for the efﬁcacy of the agents as understood by anti-
cancer drug screening programme [32]. Cyclophosphamide is
metabolized to phosphoramide mustard, which irreversibly
forms intra and inter DNA crosslink strands at guanine N-7
positions leading to cell death [33]. The probable mechanism
of 9a and 9b for their cytotoxicities is by binding to b-tubulin
as revealed by our molecular docking study. The screened IC50
values of 7, 8a–h and 9a–h are tabulated in Table 4. The IC50
values of compounds 7, 8a–h and 9a–h against HeLa cells are
represented in (Fig. 2).
3.4. Molecular docking
In relation to in vitro anticancer activity, it is worthwhile to
carry out molecular docking studies to support the in vitro
activity. A comparative and automated docking study with
newly synthesized candidate lead compounds was performed
to determine the best in silico conformation. The b-tubulin
was taken as target receptor. The Lamarckian genetic algo-
rithm, inculcated in the docking programme AutoDock 4.2,
was employed to satisfy the purpose. The structure of mod-
elled b-tubulin was obtained from (PDB ID: 1OJ0) (Fig. 3)
[34].
The molecular docking of ligand molecules 9a and 9b with
b-tubulin revealed that, compounds interacted by forming
hydrogen bonding with amino acids in the active pockets.
Docked images of 9a and 9b are shown in (Figs. 4 and 5).
The binding energy of ligand molecules 9a and 9b are depicted
in Table 5. They were seen as a good inhibitor of b-tubulin.
The anticancer activity of synthesized molecules may be
attributed to inhibition of b-tubulin and interfering with
microtubule dynamics and consequently disturbing microtu-
bule-based processes.
The ADMET properties of synthesized compounds 9a and
9b showed signiﬁcant drug scores compared to standard drug
cyclophosphamide. These result clearly indicated that further
studies are needed to assess the therapeutic efﬁciency of the
agents which gave positive results in anticancer study Table 6.
4. Conclusion
We have synthesized a series of novel azetidin-2-ones (9a–h) as
potential antimicrobial and anticancer agents. In vitro antibac-
terial studies revealed that 7, 8a–h derivatives showed out-uctive eﬀect Clog P Solubility Drug likeness Drug score
5.64 5.05 1.05 0.35
6.7 6.4 0.07 0.19
1.14 1.21 4.53 0.13
-tubulin.
. of
onds
Bonding Bond
length (A˚)
9a::DRG:HAR::b tubulin:A:ASN204:OD1 1.91
9a::DRG:HD22::b tubulin:A:ASN204:HD22 1.457
9b::DRG:OAC, NAT::b tubulin:A:CYS12:HG 1.833
S440 R. Kayarmar et al.standing inhibitory antibacterial activity against both patho-
gens. The 9a–h and few hydrazone derivatives had profound
inhibitory antibacterial activity against gram-negative patho-
gens. The antifungal screening of compounds 7, 8a–h, and
9a–h showed signiﬁcant inhibitory effects against A. fumigatus,
but poor inhibitory activity against C. albicans.We determined
their cytotoxic activity against HeLa cancer cell line, com-
pounds 9a and 9b are the most potent derivative in this series,
displayed anticancer activity with IC50 values in the range of
11.44–11.77 lg/ml against the tested cancer cell line. The pro-
tein–ligand interaction plays a signiﬁcant role in structure
based drug designing. Molecular docking study is used to clar-
ify the binding mode of the biological compound. Taken
together; our docking results show that there is a positive cor-
relation between the dock scores and the inhibition of azetidi-
nones binding protein receptor. To explore more biological
activity, it is to be concluded that the synthesized compounds
were found effective and need more validation using dynamic
studies for proper validation of the drug. Also a wide open
frame drug research can be suggested by this investigation.
5. Experimental section
5.1. General procedure
All the reagents and solvents were purchased from Spectro-
chem and Aldrich and were used without puriﬁcation. The
synthesized compounds were checked for their melting point
by the open capillary method and the purity was checked by
thin layer chromatography (TLC) on a silica plate. The IR
spectra in KBr pellets were recorded on a Shimadzu FT-IR
4100 Type. PMR spectra were recorded on a Brucker WH-
200 or on a Perkin-Elmer EM-390 (100 MHz, 300 MHz,
400 MHz) in (DMSO-d6 and CDCl3) using TMS as an internal
standard. Chemical shift values are given in d ppm scales. The
mass spectra were recorded on a MDSSCIEX/API 4000 spec-
trometer. The elemental analyses (CHN) were performed on a
CHNS-O analyser Flash EA 1112 series.
5.2. Synthesis of 2,4-drihydroxy-3-nitroquinoline (2)
Fuming nitric acid (6.29 g, 0.099 mol) was added drop wise to
the cooled mixture of 2,4-dihydroxy quinoline (10 g, 0.062 mol)
and acetic acid (7.6 ml) for 30 min, then the reaction mass was
heated for 5 h at 65 C. The product was obtained after cooling
and washing with water recrystallized from acetic acid. Yield
92%; M.p.: (198–200 C); 1H NMR: (400 MHz, CDCl3): d
7.98 (t, 2H, quinoline-H6 and H7), 8.21 (d, 2H, quinoline-H5
and H8, J= 8Hz), 11.98 (s, 2H, OH); MS: (m/z) = 207.16
(M+1). Anal. calcd. for: C9H6N2O4: C, 52.43; H, 2.93; N,
13.59; Found: C, 52.41; H, 2.91; N, 3.57%.
5.3. Synthesis of 2,4-dichloro-3-nitroquinoline (3)
2,4-hydroxy-3-nitroquinoline (2) (2 g, 0.009 mol) was added to
POCl3 (10 mL) at 65 C, and further heated for 4 h at 85–
90 C. The contents were poured onto crushed ice and neutral-
ized with 50% sodium hydroxide (10 mL). The solid obtained
was ﬁltered and recrystallized from ethanol. Yield 84%, M.p.:
(264–266 C); 1H NMR: (400 MHz, DMSO-d6): d 1.05 (d, 6H,
isopropyl-2CH3, J= 6.8 Hz), 2.15–2.17 (m, 1H, isopropyl-CH), 4.12 (d, 2H, isopropyl-CH2, J= 7.2 Hz), 6.22 (br, 1H,
NH), 7.68 (t, 2H, quinoline-H6 and H7), 8.18 (d, 2H, quino-
line-H5 and H8, J= 8 Hz); MS: (m/z) = 244.05 (M+1);
Anal. calcd. for: C9H4Cl2N2O2: C, 44.48; H, 1.66; N, 11.53;
Found: C, 44.46; H, 1.64; N, 11.53%.
5.4. Synthesis of 2-chloro-N-isobutyl-3-nitroquinoline (4)
To stirred solution of 2,4-dichloro-3-nitro quinoline (3) (2 g,
0.0082 mol) in ethanol (20 ml) K2CO3 (2.3 g, 0.0096 mol) was
added, followed by addition of isobutyl amine (0.5 g,
0.008 mol) for 30 min and continued stirring for 2 h. The solu-
tion was diluted with water and continued stirring for 1 h. The
product precipitated was washed with water and recrystallized
with ethanol. Yield 82%; M.p.: (85–88 C); 1H NMR
(400 MHz, DMSO-d6): d 1.05 (d, 6H, 2CH3, J= 6.8 Hz),
2.15–2.17 (m, 1H, CH), 4.12 (d, 2H, CH2, J= 7.2 Hz), 6.22
(br, 1H, NH), 7.70 (t, 2H, quinoline ring), 8.18 (d, 2H, quino-
line ring, J= 8 Hz); MS: (m/z) = 280.72 (M+1). Anal. calcd.
for: C13H14ClN3O2: C, 55.82; H, 5.04; N, 15.02; Found: C,
55.80; H, 5.02; N, 15.00%.
5.5. Synthesis of 2-chloro-4-isobutylquinoline-3,4-diamine (5)
To a solution of 2-Chloro-N-isobutyl-3-nitroquinoline (4) (2.5 g,
0.009 mol) in ethanol (25 ml), 5% Raney nickel was added and
2 kg/cm2 H2 pressure was applied then heated to 60 C for
17 h. The product was obtained by ﬁltering the catalyst, concen-
trating the ﬁltrate and recrystallizing from methanol. Yield 85%;
M.p.: (145–148 C); 1H NMR: (400 MHz, CDCl3) d 1.00 (d, 6H,
isopropyl-2CH3, J= 6.8 Hz), 2.30–2.40 (m, 1H, isopropyl-CH),
3.91 (b, 2H, NH2), 4.05 (d, 2H, isopropyl-CH2, J= 7.2 Hz), 6.92
(br, 1H, NH), 7.65 (t, 2H, quinoline-H6 and H7), 8.02 (d, 2H,
quinoline-H5 and H8, J= 8Hz); MS: (m/z) = 250.74 (M+1).
Anal. calcd. for C13H16N3: C, 62.52; H, 6.46; N, 16.83; Found:
C,62.50; H, 6.44; N, 16.81%.
5.6. Synthesis of 4-chloro-1-isobutyl-1H-imidazo[4,5-
c]quinoline (6)
2-Chloro-4-isobutylquinoline-3,4-diamine (5) (2 g 0.008 mol) and
triethyl orthoformate (8 mL) were heated to 80 C for 3 h. The
product was isolated by distilling triethyl orthoformate under
vacuum at 60–65 C. The solid was dissolved in CHCl3, washed
with water, dried over Na2SO4 and distilled. The product was
recrystallized from methanol. Yield 75%; M.p.: (139–140 C);
IR (KBr tmax/cm
1), 3038 (Ar–H), 2960 (C–H), 1576 (C‚N),
1542 (C‚C), 877 (C–Cl). 1H NMR: (400 MHz, CDCl3) d 1.04
(d, 6H, isopropyl-2CH3, J= 6.8 Hz), 2.36–2.44 (m, 1H, isopro-
pyl-CH), 4.34 (d, 2H, isopropyl-CH2, J= 7.2 Hz), 7.68 (t, 2H,
quinoline-H7 and H8), 8.36 (d, 2H, quinoline-H6 and H9),
8.50 (s, 1H, imidzole-H2); MS: (m/z) = 260.73 (M+1): Anal.
calcd. for: C14H14ClN3: C, 64.74; H, 5.43; N, 16.18; Found: C,
64.72; H, 5.41; N, 16.16%.
5.7. Synthesis of 4-hydrazino-1-isobutyl-1H-imidazo[4,5-
c]quinoline (7)
4-Chloro-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline (6)
(10 g, 0.03 mol) and 80% hydrazine hydrate (25 ml) in ethanol
were reﬂuxed for 9 h. The solid formed was cooled, ﬁltered,
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200 C); IR (KBr, cm1), 3388, 3394 (NH), 3085 (Ar–H),
2957 (C–H), 1564 (C‚C), 1174 (C–N), 1039 (N–N), 877.7
(C–Cl); 1H NMR: (400 MHz, CDCl3): d 1.02 (d, 6H, 2CH3,
J= 6.8 Hz), 2.30–2.40 (m, 1H, CH), 4.28 (d, 2H, CH2,
J= 7.2 Hz), 4.76 (br, 2H, NH2), 7.14 (s, 1H, NH), 7.38 (t,
1H, quinoline ring), 7.57 (t, 1H, quinoline ring), 7.76 (s, 1H,
imidazole ring), 7.87 (d, 1H, J= 7.9 Hz, 1H, quinoline ring),
7.95 (d, 1H, J= 7.9 Hz, quinoline ring). 13C NMR:
(100 MHz, CDCl3): d 19.77 (–2CH3 of isopropyl), 28.81(–CH
of isopropyl), 55.04 (–CH2 of isopropyl), 115.69, 120.0,
122.70, 127.37, 127.73, 128.02, 132.17, 142.31, 145.03, 152.28;
MS: (m/z) = 256.32 (M+1). Anal. calcd. For: C14H17N5:
C, 65.86; H, 6.71; N, 27.43; Found: C, 65.84; H, 6.69; N,
27.41%.
5.8. General procedure for the synthesis of 4-(substituted
arylidenyliminoamino) 1-isobutyl-1H-imidazo[4,5-c]quinoline
(8a–h)
A mixture of (7) (0.01 mol), and the appropriate aldehydes
(0.01 mol) in absolute ethanol (10 ml) containing acetic acid
(0.5 ml) was heated under reﬂux for 8 h. The solid separated
was ﬁltered washed, dried, and recrystallized from ethanol.
5.8.1. 4-(4-Chlorophenylidenyliminoamino)1-isobutyl-1H-
imidazo[4,5-c]quinoline (8a)
Yield 96%; M.p.: (258–260 C). IR (KBr, tmax/cm1), 3371
(NH), 3058 (Ar–H), 2957 (C–H), 1590 (C‚N); 1H NMR
(400 MHz, CDCl3) d 1.04 (d, 6H, J= 6.8 Hz, 2CH3), 2.32–
2.42 (m, 1H, CH), 4.38 (d, 2H, J= 7.2 Hz, CH2), 7.24–7.28
(m, 4H, phenyl ring), 7.39 (s, 1H, NH), 7.70 (t, 2H, quinoline
ring), 7.89 (s, 1H, imidazole ring), 8.16 (d, 1H, J= 8 Hz, quin-
oline ring), 8.30 (d, 1H, J= 8 Hz, quinoline ring), 9.67 (ss, 1H,
CH‚N); 13C NMR: (100 MHz, CDCl3) d 19.69 (2CH3 of iso-
propyl), 28.77 (CH of isopropyl), 55.98 (CH2 of isopropyl),
113.40, 116.07, 120.48, 121.66, 121.74, 127.90, 128.58, 130.43,
131.64, 132.13, 134.06, 135.05, 136.39, 142.73, 145.21, 148.83,
152.40; MS: (m/z) = 378.87 (M+1); Anal. calcd. for: C21H20-
Cl1N5: C, 66.75; H, 5.33; N, 18.53; Found: C, 66.73; H, 5.31;
N, 8.51%.
5.8.2. 4-(Biphenylidenyliminoamino)1-isobutyl-1H-
imidazo[4,5-c] quinoline (8b)
Yield 90%; M.p.: (146–148 C); IR (KBr, tmax/cm1), 3236
(NH), 3049 (Ar–H), 2957 (C–H), 1583(C‚N); 1H NMR
(400 MHz, CDCl3): d 0.96 (d, 6H, J= 6.8 Hz, 2CH3), 2.32–
2.42(m, 1H, CH), 4.37 (d, 2H, J= 7.2 Hz, CH2), 7.30–7.34
(m, 3H, biphenyl ring), 7.41 (d, 2H, J= 8 Hz, biphenyl ring),
7.50 (d, 4H, J= 8 Hz, biphenyl ring), 7.63 (s, 1H, NH), 7.76
(t, 2H, quinoline ring), 7.81 (s, 1H, CH, imidazole ring), 7.82
(d, 1H, J= 8 Hz, quinoline ring), 7.89 (d, 1H, J= 8 Hz, quin-
oline ring), 9.28 (ss, 1H, CH‚N); 13C NMR: (100 MHz,
CDCl3) d ppm 19.69 (2CH3 of isopropyl), 28.70 (CH of isopro-
pyl), 55.06 (CH2 of isopropyl), 114.30, 116.95, 118.73, 120.33,
121.62, 122.12, 122.48, 126.14, 126.97, 127.13, 127.50, 127.66,
127.93, 127.98, 128.77, 129.19, 140.49, 142.74, 144.09, 145.90,
147.52, 148.69, 149.04; MS: (m/z) = 420.52(M+1); Anal.
calcd. for: C27H25N5: C, 77.30; H, 6.01; N, 16.69; Found: C,
77.28; H, 5.9; N; 16.67%.5.8.3. 4-(2,4-Dimethoxyphenylidenyliminoamino)1-isobutyl-
1H-imidazo[4,5-c]quinoline (8c)
Yield 80%; M.p.: (118–120 C); IR (KBr, tmax/cm1), 3265 (NH),
3050 (Ar–H), 2957 (C–H), 1547 (C‚N); 1H NMR (400 MHz,
CDCl3): d 0.99 (d, 6H, J= 6.8 Hz, 2CH3), 2.32–2.42 (m, 1H,
CH), 3.92 (s, 3H, OCH3), 4.02 (s, 3H, OCH3), 4.38 (d, 2H,
J= 7.2 Hz, CH2), 6.89 (s, 1H, 2,4 (OCH3)2-phenyl ring), 7.00
(d, 2H, J= 8.0 Hz, phenyl ring) 7.30 (d, 2H, J=8.0 Hz, phenyl
ring), 7.30 (d, 2H, J= 8.0 Hz, phenyl ring), 7.73 (t, 2H, quinoline
ring), 7.78 (s,1H, NH), 7.82 (s, 1H, imidazole ring), 8.15 (d, 1H,
J= 8Hz, quinoline ring), 8.28 (d, 1H, J=8Hz, quinoline ring),
9.60 (ss, 1H, CH‚N); 13C NMR: (100 MHz, CDCl3): d 19.69
(2CH3 of isopropyl), 28.75 (CH of isopropyl), 55.00 (CH2 of iso-
propyl), 55.35 (2OCH3 of phenyl ring), 113.35, 116.00, 120.40,
121.63, 121.70, 127.85, 128.55, 130.40, 131.60, 132.10, 134.00,
135.00, 136.30, 142.70, 145.20, 148.83, 152.39; MS: (m/
z) = 404.48 (M+1); Anal. calcd. for: C23H25N5O2: C, 68.47; H,
6.25; N, 17.36: Found: C, 68.45;H, 6.23; N, 17.34%.
5.8.4. 4-(2,4-Dimethoxy-5-nitrophenylidenyliminoamino)
1-isobutyl-1H-imidazo[4,5-c]quinoline (8d)
Yield 55%; M.p.: (216–218 C); IR (KBr, tmax/cm1), 3368
(NH), 3060 (Ar–H), 2958 (C–H), 1595 (C‚N); 1H NMR:
(400 MHz, CDCl3): d 0.98 (d, 6H, J= 6.8 Hz, 2CH3), 2.30–
2.40 (m, 1H, CH), 3.99 (s, 3H, OCH3), 4.08 (s, 3H, OCH3),
4.38 (d, 2H, J= 7.2 Hz, CH2), 6.95 (s, 2H, phenyl ring),
7.38 (s, 1H, phenyl ring), 7.69 (1H, NH), 7.78 (t, 2H quinoline
ring), 7.85 (s, 1H, imidazole ring), 8.16 (d, 1H, J= 8 Hz, quin-
oline ring), 8.30 (d, 1H, J= 8 Hz, quinoline ring), 9.70 (ss, 1H,
CH‚N); 13C NMR: (100 MHz, CDCl3): d 19.70 (2CH3 of iso-
propyl), 28.80 (CH of isopropyl), 55.05 (CH2 of isopropyl),
55.38 (2OCH3 of phenyl ring), 113.38, 116.05, 120.45,
121.64, 121.75, 127.86, 128.60, 130.45, 131.65, 132.12, 134.05,
135.05, 136.35, 142.75, 145.25, 148.85, 152.40. MS: (m/
z) = 449.48 (M+1); Anal. calcd. for: C23H24N6O4: C, 61.60;
H, 5.39; N, 18.74; Found: C, 61.58; H, 5.37; N, 18.72%.
5.8.5. 4-(2-Methoxy-4-hydroxy-5-
nitrophenylidenyliminoamino)1-isobutyl-1H-imidazo[4,5-
c]quinoline (8e)
Yield 66%, M.p.: (155–156 C). IR (KBr, tmax/cm1) 3375
(NH), 3063 (Ar–H), 2958 (C–H), 1598 (C‚N); 1H NMR
(400 MHz, CDCl3): d 0.99 (d, 6H, J= 6.8 Hz, 2CH3), 231–
2.41 (m, 1H, CH), 3.78 (s, 3H, OCH3), 4.40 (d, 2H,
J= 7.2 Hz, CH2), 6.91 (s, 2H, phenyl ring) 7.31 (s, 2H, phe-
nyl), 7.76 (t, 2H, quinoline ring), 7.78 (s, 1H, NH), 7.89 (s,
1H, imidazole ring), 8.21 (d, 1H, J= 8 Hz, quinoline ring),
8.32 (d, 1H, J= 8 Hz, quinoline ring), 9.75 (ss, 1H, CH‚N),
13.00 (s, 1H, OH); 13C NMR: (100 MHz, CDCl3): d 19.71
(2CH3 of isopropyl), 28.80 (CH of isopropyl), 55.05 (CH2 of
isopropyl), 55.39 (OCH3 of phenyl ring), 113.39, 116.06,
120.46, 121.64, 121.77, 127.71, 128.61, 130.46, 131.66, 132.12,
134.66, 135.06, 136.36, 142.77, 145.26, 148.88, 152.40; MS:
(m/z) = 435.45 (M+1). Anal. calcd. for: C22H22N6O4: C,
60.82; H, 5.10; N, 19.34; Found: C, 60.80; H, 5.08; N, 19.32%.
5.8.6. 4-(6-Methoxynapthylidenyliminoamino)1-isobutyl-1H-
imidazo[4,5-c]quinoline (8f)
Yield 84%; M.p.: (158–160 C); IR (KBr, tmax/cm1), 3338
(NH), 3050 (Ar–H), 2957 (C–H), 1588 (C‚N); 1H NMR
S442 R. Kayarmar et al.(400 MHz, CDCl3) d 0.91 (d, 6H, J= 6.8 Hz, 2CH3), 2.30–
2.40 (m, 1H, CH), 3.90 (s, 3H, OCH3), 4.38 (d, 2H,
J= 7.2 Hz, CH2), 7.08 (d, 2H, J= 6 Hz, naphthyl ring),
7.24 (s, 1H, naphthyl ring), 7.50 (s, 1H, naphthyl ring), 7.54
(d, 2H, J= 6 Hz, naphthyl ring), 7.76 (t, 2H, quinoline ring),
7.90 (s, 1H, NH), 7.92 (s, 1H, imidazole ring), 8.20 (d, 1H,
J= 8 Hz, quinoline ring), 8.30 (d, 1H, J= 8 Hz, quinoline
ring), 9.30 (ss, 1H, CH‚N); 13C NMR: (100 MHz, CDCl3):
d 19.69 (2CH3 of isopropyl), 28.70(CH of isopropyl), 55.06
(CH2 of isopropyl), 55.38 (OCH3 of naphthyl ring), 114.31,
116.96, 118.74, 120.34, 121.63, 122.13, 122.49, 126.14, 126.98,
127.14, 127.50, 127.67, 127.94, 127.99, 128.78, 129.20, 140.50,
142.75, 145.90, 147.53, 148.69, 149.04; MS: (m/z) = 424.51
(M+1); Anal. calcd. for: C26H25N5O: C, 73.74; H, 5.95; N,
16.54; Found: C, 73.72; H, 5.93; N, 16.52%.
5.8.7. 4-(4-Hydroxyphenylidenyliminoamino)1-isobutyl-1H-
imidazo[4,5-c]quinoline (8g)
Yield 60%, M.p.: (238–240 C); IR (KBr, tmax/cm1), 3401
(OH), 3339 (NH), 3053 (Ar–H), 2957 (C–H), 1592 (C‚N);
1H NMR: (400 MHz, CDCl3): d 1.02 (d, 6H, J= 6.8 Hz,
2CH3), 2.30–2.40 (m, 1H, CH), 4.40 (d, 2H, J= 7.2 Hz,
CH2), 7.20 (d, 2H, J= 8 Hz, phenyl ring), 7.28 (d, 2H,
J= 8 Hz, phenyl ring), 7.65 (s, 1H, NH), 7.68 (t, 2H, quino-
line ring), 7.90 (s, 1H, imidazole ring), 8.15 (d, 1H,
J= 8 Hz, quinoline ring), 8.30 (d, 1H, J= 8Hz, quinoline
ring), 9.60 (ss, 1H, CH‚N), 13.00 (s, 1H, OH); 13C NMR:
(100 MHz,CDCl3): d 19.69 (2CH3 of isopropyl), 28.77 (CH
of isopropyl), 55.98 (CH2 of isopropyl), 113.39, 116.06,
120.46, 121.63, 121.73, 127.89, 128.57, 130.42, 131.63, 132.16,
134.05, 135.05, 136.38, 142.70, 145.20, 148.83, 152.40; MS:
(m/z) = 360.42 (M+1); Anal. calcd. for: C21H21 N5O: C,
70.17; H, 5.89; N, 19.48; Found: C, 70.15; H, 5.87; N, 19.46%.
5.8.8. 4-(2,4-Dichlorophenylidenyliminoamino)-1-isobutyl-1H-
imidazo[4,5-c]quinoline (8h)
Yield 65%; M.p.: (198–200 C); IR (KBr, tmax/cm1), 3375
(NH), 3010 (Ar–H), 2958 (C–H), 1595 (C‚N); 1H NMR:
(400 MHz, CDCl3): d 1.04 (d, 6H, J= 6.8 Hz, 2CH3), 2.32–
2.42 (m, 1H, CH2), 4.38 (d, 1H, J= 7.2 Hz, CH2), 7.25 (d,
2H, J= 8 Hz, phenyl), 7.28 (s, 1H, phenyl), 7.73 (t, 2H, quin-
oline ring), 7.78 (s, 1H, NH), 7.90 (s, 1H, imidazole ring), 8.16
(d, 1H, J= 8 Hz, quinoline ring), 8.30 (d, 1H, J= 8 Hz, quin-
oline ring), 9.70 (ss, 1H, CH‚N); 13C NMR: (100 MHz,
CDCl3): d 19.69 (2CH3 of isopropyl), 28.77 (CH of isopropyl),
55.98 (CH2 of isopropyl), 113.43, 116.11, 120.51, 121.70,
121.78, 127.94, 128.62, 130.47, 131.68, 132.17, 134.10, 135.09,
136.41, 142.75, 145.25, 148.85, 152.44; MS: (m/z) = 412.32
(M+1); Anal. calcd. for: C21H19Cl2N5: C, 61.17; H, 4.64; N,
16.99; Found: C, 61.15; H, 4.62; N, 16.97%.5.9. General procedure for the synthesis of 3-chloro-4-
(substituted)-1-[(1-isobutyl-1H-imidazo[4,5-c]quinolin-4-
yl)amino]azetidin-2-ones (9a–h)
Chloroacetyl chloride (0.02 mol) was added to (8a–h)
(0.01 mol) and triethylamine (0.02 mol) in DMF (25 ml) at
5–10 C. The mixture was stirred for 6 h at room temperature.
The triethylamine hydrochloride formed was ﬁltered. The ﬁl-
trate was quenched to water. The solid separated was ﬁlteredand crude product was puriﬁed by silica-gel chromatography
with hexane–ethyl acetate (4:1) as the mobile phase.
5.9.1. 3-Chloro-4-(4-chlorophenyl)-1-[(1-isobutyl-1H-
imidazo[4,5-c]quinolin-4-yl)amino] azetidin-2-one (9a)
Yield 80%; M.p.: (178–180 C); IR (KBr, tmax/cm1), 3369
(NH), 3056 (Ar–H), 2955 (C–H), 1765 (C‚O); 762 (C–Cl);
1H NMR: (400 MHz, CDCl3): d 1.09 (d, 6H, J= 6.8 Hz,
2CH3), 2.38–2.43 (m, 1H, CH), 4.39 (d, 2H, J= 7.2 Hz),
5.02 (d, 1H, J= 6 Hz, CH of azetidinone ring), 7.26–7.30
(m, 4H, phenyl), 7.36 (1H, NH), 7.48 (d, 1H, J= 8.4 Hz,
CH of azetidinone ring), 7.77 (t, 2H, quinoline ring), 7.92 (s,
1H, imidazole ring), 8.19 (d, 1H, J= 8 Hz, quinoline ring),
8.31 (d, 1H, J= 8 Hz quinoline ring); 13C NMR: (100 MHz
CDCl3): d 19.90 (2CH3 of isopropyl), 28.93 (CH of isopropyl),
55.29 (CH2 of isopropyl), 65.01 (CH of azetidinone ring), 70.81
(CH of azetidinone ring), 118.73, 120.22, 121.52, 128.00,
128.05, 128.62, 128.91, 131.31, 132.32, 134.55, 135.84, 136.14,
142.14, 142.59, 143.95, 144.97, 167.82 (–CO–); MS: (m/
z) = 455.35 (M+1); Anal. calcd. for: C23H21Cl2N5: C, 60.80;
H, 4.66; N,15.41; Found: C, 60.78; H, 4.64; N, 15.39%.
5.9.2. 4-Biphenyl-4-yl-3-chloro-1-[(1-isobutyl-1H-imidazo[4,5-
c]quinolin-4-yl)amino] azetidin-2-one (9b)
Yield 90%, M.p.: (202–204 C). IR (KBr, tmax/cm1), 3234
(NH), 3047 (Ar–H), 2957 (C–H), 1760 (C‚O), 762 (C–Cl);
1H NMR (400 MHz, CDCl3) d 1.08 (d, 6H, J= 6.8 Hz,
2CH3), 2.33–2.43 (m, 1H, CH), 4.38 (d, 2H, J= 7.2 Hz,
CH2), 5.09 (d, 1H, J= 6 Hz CH of azetidinone ring), 7.36
(d, 3H, biphenyl ring), 7.43 (d, 2H, J= 8 Hz, biphenyl ring),
7.52 (d, 4H, J= 8 Hz, biphenyl ring), 7.61 (d, 1H,
J= 8.4 Hz, CH of azetidinone ring), 7.64 (1H, NH), 7.76 (t,
2H of quinoline ring), 7.93 (s, 1H, imidazole ring), 8.19 (d,
1H J= 8 Hz, quinoline ring), 8.32 (d, 1H J= 8 Hz, quinoline
ring); 13C NMR: (100 MHz, CDCl3): d 19.91 (2CH3 of isopro-
pyl), 28.93 (CH of isopropyl), 55.28 (CH2 of isopropyl), 65.31
(CH of azetidinone ring), 70.90 (CH of azetidinone ring),
118.73, 120.23, 121.50, 127.04, 127.26, 127.78, 127.95,
127.99,128.03, 128.87, 131.31, 132.75, 134.54, 135.81, 136.10,
140.21, 142.96, 143.25, 143.98, 144.96, 145.91, 147.53, 167.89;
MS: (m/z) = 497.00 (M+1); Anal. calcd. for: C29H26ClN5O:
C, 70.22; H, 5.28; N, 14.12; Found: C, 70.20; H, 5.26; N,
14.10%.
5.9.3. 3-Chloro-4-(2,4-dimethoxyphenyl)-1-[(1-isobutyl-1H-
imidazo[4,5-c]quinolin-4-yl)amino] azetidin-2-one (9c)
Yield 92%; M.p.: (132–134 C); IR (KBr, tmax/cm1), 3264
(NH), 3048 (Ar–H), 2955 (C–H), 1745 (C‚O); 1HNMR
(400 MHz, CDCl3) d 1.09 (d, 6H, J= 6.8 Hz, 2CH3), 2.33–
2.43 (m, 1H, CH), 3.77 (s, 6H, 2OCH3), 4.41 (d, 2H,
J= 7.2 Hz, CH2), 5.02 (d, 1H, J= 6 Hz, CH of azetidinone
ring), 7.26 (s, 1H, phenyl), 7.31 (d, 2H, J= 8.0 Hz, Phenyl),
7.70 (d, 1H, J= 8.4 Hz, CH of azetidinone ring), 7.73 (t,
2H, quinoline ring), 7.79 (1H, NH), 7.93 (s, 1H, imidazole
ring), 8.19 (d, 1H, J= 8 Hz, quinoline ring), 8.30 (d, 1H,
J= 8 Hz, quinoline ring); 13C NMR: (100 MHz, CDCl3): d
19.90 (2CH3 of isopropyl), 28.93 (CH of isopropyl), 55.29
(CH2 of isopropyl), 55.35 (2OCH3 of phenyl ring), 65.00
(CH of azetidinone ring), 70.80 (CH of azetidinone ring),
118.72, 120.20, 121.84, 127.99, 128.00, 128.60, 128.90, 131.30,
132.30, 134.50, 135.80, 136.10, 142.10, 142.50, 143.90, 144.90,
Synthesis and characterization of imidazoquinoline based 2-azetidinones S443167.80 (–CO–). MS: (m/z) = 464.96 (M+1). Anal. calcd. for:
C25H26ClN5O2: C, 62.56; H, 5.46; N, 14.59 Found: C, 62.54;
H, 5.44; N, 14.57%.
5.9.4. 3-Chloro-4-(2,4-dimethoxy,5-nitrophenyl)-1-
[(1-isobutyl-1H-imidazo[4,5-c]quinolin-4-yl)amino] azetidin-
2-one (9d)
Yield 92% M.p.: (206–208 C). IR (KBr, tmax/cm1), 3366
(NH), 3059 (Ar–H), 2957 (C–H), 1750 (C‚O; 1H NMR
(400 MHz, CDCl3) d 1.08 (d, 6H, J= 6.8 Hz, 2CH3), 2.33–
2.43 (m, 1H, CH), 3.78 (s, 3H, OCH3), 3.85 (s, 3H, OCH3),
4.40 (d, 2H, J= 7.2 Hz, CH2), 5.10 (d, 1H, J= 6 Hz, CH aze-
tidinone ring), 7.28 (s, 2H, phenyl), 7.74 (t, 2H, quinoline ring),
7.77 (d, 1H, J= 8.4 Hz, CH of azetidinone ring), 7.80 (1H,
NH), 7.93 (s, 1H, imidazole ring), 8.20 (d, 1H, J= 8 Hz, quin-
oline ring, 7.9 Hz), 8.31 (d, 1H, J= 8 Hz, quinoline ring); 13C
NMR: (100 MHz, CDCl3): d 19.91 (2CH3 of isopropyl), 28.94
(CH of isopropyl), 55.30 (CH2 of isopropyl), 55.38 (2OCH3 of
phenyl ring), 65.01 (CH of azetidinone ring), 70.81 (CH of aze-
tidinone ring), 118.73, 120.21, 121.65, 128.00, 128.01, 128.61,
128.91, 131.31, 132.31, 134.51, 135.81, 136.11, 142.11, 142.51,
143.91, 144.91, 167.81 (–CO–); MS: (m/z) = 525.96 (M+1);
Anal. calcd. for: C25H25ClN6O5: C, 57.20; H, 4.80; N, 16.01;
Found: C, 56.18; H, 4.78; N, 15.99%.
5.9.5. 3-Chloro-4-(4-hydroxy,3-methoxy,5-nitrophenyl)-1-[(1-
isobutyl-1H-imidazo[4,5-c]quinolin-4-yl)amino] azetidin-2-one
(9e)
Yield 50%; M.p.: 168–170 C; IR (KBr, tmax/cm1), 3400
(OH), 3371 (NH), 3060 (Ar–H), 2957 (C–H), 1751 (C‚O);
1H NMR (400 MHz, CDCl3): d 1.09 (d, 6H, J= 6.8 Hz,
2CH3), 2.34–2.41 (m, 1H, CH), 3.79 (s, 3H, OCH3), 4.42 (d,
2H, J= 7.2 Hz, CH2), 5.11(d, 1H, J= 6 Hz, CH of azetidi-
none ring), 7.32 (s, 2H, phenyl), 7.78 (d, 1H, J= 8.4 Hz,
CH phenyl of azetidinone ring), 7.79 (t, 2H, quinoline ring),
7.81 (1H, NH), 7.99 (s, 1H, CH, imidazole ring), 8.23 (d,
1H, J= 8 Hz quinoline ring), 8.34 (d, 1H, J= 7.7 Hz, quino-
line ring), 13.10 (s, 1H, OH); 13C NMR: (100 MHz, CDCl3) d
19.91 (2CH3 of isopropyl), 28.90 (CH of isopropyl), 55.31
(CH2 of isopropyl), 55.39 (OCH3 of phenyl ring), 65.02 (CH
of azetidinone ring), 70.82 (CH of azetidinone ring), 118.74,
120.22, 121.67 128.02, 128.04, 128.62, 128.92, 131.32, 132.34,
134.52, 135.82, 136.12, 142.12, 142.50, 143.90, 144.90, 167.85
(–CO–); MS: (m/z) = 511.96 (M+1); Anal. calcd. for: C24H23-
ClN6O5: C, 56.42; H, 4.54; N, 16.54; Found: C, 56.40; H, 4.52;
N, 16.52%.
5.9.6. 3-Chloro-4-(6-methoxy-2-napthyl)-1-[(1-isobutyl-1H-
imidazo[4,5-c]quinolin-4-yl)amino] azetidin-2-one (9f)
Yield 80%; M.p.: (204–206 C); IR (KBr, tmax/cm1), 3335
(NH), 3049 (Ar–H), 2955 (C–H), 1750 (C‚O); 1H NMR
(400 MHz, CDCl3) d ppm 1.09 (d, 6H, J= 6.8 Hz, 2CH3),
2.38–2.43 (m, 1H, CH), 3.91 (s, 3H, OCH3), 4.39 (d, 2H,
J= 7.2 Hz, CH2), 5.02. (d, 1H, J= 6 Hz, CH of azetidinone
ring,), 7.08 (d, 2H, J= 6 Hz, naphthyl ring), 7.26 (s, 1H,
naphthyl ring), 7.53 (s, 1H, naphthyl ring), 7.59 (d, 2H,
J= 6Hz, naphthyl ring), 7.72 (d, 1H, J= 8 4 Hz, CH of aze-
tidinone ring), 7.78 (t, 2H, quinoline ring), 7. 92 (1H, NH), 7
.94 (s, 1H, CH, imidazole ring), 8.24 (d, 1H, J= 8 Hz, quino-
line ring), 8.34 (d,1H, J= 8 Hz, quinoline ring); 13C NMR:(100 MHz, CDCl3): d ppm 19.92 (2CH3 of isopropyl), 28.93
(CH of isopropyl), 55.28 (CH2 of isopropyl), 55.36 (OCH3 of
naphthyl ring) 65.33 (CH of azetidinone ring), 70.91 (CH of
azetidinone ring), 118.74, 120.24, 121.51, 127.05, 127.27,
127.79, 127.96,128.00, 128.88, 131.32, 132.76, 134.56, 135.82,
136.12, 140.22, 142.98, 143.26, 143.99, 144.98, 145.91, 167.90;
MS: (m/z) = 500.99 (M+1); Anal. calcd. for: C28H26ClN5O2:
C, 67.26; H, 5.24; N, 14.01; Found: C, 67.24; H, 5.22; N,
13.99%.
5.9.7. 3-Chloro-4-(4-hydroxyphenyl)-1-[(1-isobutyl-1H-
imidazo[4,5-c]quinolin-4-yl)amino] azetidin-2-one (9g)
Yield 60%; M.p.: (236–238 C); IR (KBr, tmax/cm1), 3400 (–
OH), 3338 (NH), 3050 (Ar–H), 2955 (C–H), 1755 (C‚O); 1H
NMR: (400 MHz, CDCl3): d 1.08 (d, 6H, J= 6.8 Hz, 2CH3),
2.36–2.43 (m, 1H, CH), 4.39 (d, 2H, J= 7.2 Hz, CH2), 5.01 (d,
1H, J= 6 Hz, CH of azetidinone ring), 7.30 (d, 4H, J= 8 Hz,
phenyl), 7.59 (d, 1H, J= 8 Hz, CH of azetidinone ring), 7.68
(1H, NH), 7.75 (t, 2H, quinoline ring), 7.91 (1H, CH, Imidaz-
ole ring), 8.19 (d, 1H, J= 8 Hz, Quinoline ring), 8.32 (d, 1H,
J= 8 Hz, Quinoline ring), 13.00 (s, 1H, OH); 13C NMR:
(100 MHz, CDCl3): d 19.91 (2CH3 of isopropyl), 28.92 (CH
of isopropyl), 55.28 (CH2 of isopropyl), 65.00 (CH of azetidi-
none ring), 70.80 (CH of azetidinone ring), 118.72, 120.20,
121.53, 127.99, 128.04, 128.60, 128.90, 131.30, 132.30, 134.54,
135.83, 136.13, 142.13, 142.58, 143.94, 144.96, 167.80 (–CO–);
MS: (m/z) = 436.91 (M+1); Anal. calcd. for: C23H22ClN5O2:
C, 63.37; H, 5.09; N, 16.07; Found: C, 63.35; H, 5.07; N,
16.05%.
5.9.8. 3-Chloro-4-(2,4-dichlorophenyl)-1-[(1-isobutyl-1H-
imidazo[4,5-c]quinolin-4-yl)amino] azetidin-2-one (9h)
Yield 84%; M.p.: (182–184 0C); IR (KBr, tmax/cm
1), 3370
(NH), 3091 (Ar–H), 2956 (C–H), 1770 (C‚O); 1H NMR:
(400 MHz, CDCl3): d 1.07 (d, 6H, J= 6.8 Hz, 2CH3), 2.36–
2.43 (m, 1H, CH), 4.39 (d, 2H, J= 7.2 Hz, CH2), 5.03 (d,
1H, J= 6 Hz, CH of azetidinone ring), 7.27 (d, 2H,
J= 8 Hz, phenyl), 7.30 (s, 1H, phenyl), 7.75 (t, 2H, quinoline
ring), 7.79 (1H, NH), 7.93 (s, 1H, CH, imidazole ring), 8.02 (d,
1H, J= 8 Hz, CH of azetidinone ring), 8.19 (d, 1H, J= 8 Hz
quinoline ring), 8.33(d, 1H, J= 8 Hz, quinoline ring); 13C
NMR: (100 MHz, CDCl3): d 19.83 (2CH3 of isopropyl),
28.88 (CH of isopropyl), 55.31 (CH2 of isopropyl), 65.30
(CH of azetidinone ring), 70.98 (CH of azetidinone ring),
118.73, 120.24, 121.54, 127.63, 128.05, 129.5, 129.98, 131.24,
134.32, 134.85, 135.82, 136.42, 139.16, 142.27, 143.95, 144.97,
167.84; MS: (m/z)= 489.79 (M+1); Anal. calcd. for: C23H20-
Cl3N5O: C, 56.52; H, 4.12; N, 14.33; Found: C, 56.50; H,
4.10; N, 14.31%.
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